Illumina Reports Q3 Net Income of $220 Million

The San Diego-based firm outperformed analyst earnings estimates during the third quarter of 2026.

Updated on Oct. 29, 2026 in Economic Indicators

Illumina Reports Q3 Net Income of $220 Million

Live Poll

Does consistent performance by major companies increase your confidence in the economy?

Illumina reported third-quarter net income of $220 million, or $1.43 per share. This performance beat Wall Street analyst expectations of $1.36 per share.

Why it matters

The company outperformed earnings forecasts despite missing revenue targets, providing a key look into the health of the genomics sector. Investors now look toward the firm's full-year projections to gauge ongoing market stability.

Illumina reported $1.13 billion in total revenue for the period, narrowly missing the $1.14 billion forecast by analysts. The company posted adjusted earnings of $1.44 per share.

The players

Illumina

A San Diego-based biotechnology company that specializes in DNA sequencing and array-based technologies.

The details

The San Diego-headquartered biotechnology company finalized its third-quarter results, maintaining a focus on its projected annual performance. Full-year guidance remains between $5.40 and $5.45 per share with revenue estimates set between $4.64 billion and $4.66 billion.

The fiscal results cover the third quarter of 2026.

Macro View

Illumina's earnings report follows the broader industry trend of genomic sequencing adoption across clinical diagnostic settings. These results mirror historical patterns where firms scale revenue alongside the expanding integration of precision medicine into healthcare.

For shareholders and potential investors, these quarterly figures provide a clearer picture of the company's fiscal trajectory heading into the end of the year. The earnings beat may influence market sentiment regarding the company's valuation in the coming months.

The takeaway

Illumina's ability to exceed earnings per share expectations despite a revenue shortfall highlights a focus on operational efficiency. Investors should monitor whether the company meets its full-year revenue projections of up to $4.66 billion.